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32p Analysis of DNA Adducts in Tissues of
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by M. Vijayaraj Reddy,* Gary R. Blackburn,* Ceinwen A.
Schreiner,* Myron A. Mehiman,* and Carl R. Mackerer*
Solid tumors have been reported in the Zymbal gland, oral and nasal cavities, liver, and mammary gland
ofSprague-Dawley rats followingchronic, high-dose administration ofbenzene. The carcinogenic activity
ofbenzene is thought to be caused by activation to toxic metabolites that can interact with DNA, forming
covalent adducts. A nuclease Pi-enhanced 32P-postlabeling assay, having a sensitivity limit of 1 adduct in
109-10 DNA nucleotides, was found suitable for measuring aromatic DNA adducts derived in vitro from
catechol, benzenetriol (BT), phenol, hydroquinone (HQ), and benzoquinone (BQ), potential metabolites of
benzene. When DNA specimens isolated from tissues offemale SpraguewDawley rats at 24 hr after an oral
gavage dose of200to500mg/kg, 5days/week, in olive oil (3 mL/kg) for 1 day, 1 week, 5 weeks, and 10weeks
were analyzed bythe 32P-postlabeling procedure, noaromatic adducts weredetected unequivocally with DNA
samples ofliver, kidney, bone marrow, andmammary gland. With Zymbal glandDNA, three weak spots at
levels totaling four lesions per 109 DNA nucleotides were seen only after 10 weeks oftreatment, and these
adducts didnotcorrespondchromatographically tomajoradducts in vitrofromthe abovespecifiedcompounds.
Consequently, this finding requires confirmatory experiments. This distinct adduct pattern may relate to
tumorinduction inthis organ followingbenzene administration. Ourresults alsoindicate thatDNAadducts
derivedfrom catechol, BT, phenol, HQ, andBQare eithernotformed in vivowith benzene orformedat levels
below the detection limit of 1 adduct per 10910 DNA nucleotides.
Introduction
Benzene is achemical intermediate usedfor the synthe-
sis ofpesticides, dyes, andplastic resins, a component of
commercial gasoline, and is present in air, food, feed,
tobacco, and pyrolysis products (1). According to the in-
vestigations of Maltoni et al. (2) and the National Toxi-
cology Program(3), the chronic, high-dose administration
ofbenzene to rats produces a variety oftumors, includ-
ing Zymbal gland carcinomas, oral cavity carcinomas,
hepatocarcinomas, and possibly, mammary carcinomas.
Studies on the mechanisms of carcinogenic action of
benzene have focused on its conversion to toxic metabo-
lites and its ability to damage DNA, Evidence suggests
that benzene is hydroxylated in vivo to phenol and
catechol (4,5). Phenol, which is the predominantproduct,
can be further converted via ahydroquinone (HQ) inter-
mediate to semiquinone andbenzoquinone (BQ). Catechol
may form either 1,2,4-benzenetriol (BT), which can be ox-
idized to its semiquinone and quinone species, or to the
ring-opened product, trans,trans-muconaldehyde (4-6).
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Semiquinones and quinones are generally considered to
be toxic metabolites capable of interacting with DNA
(7,8), but the genotoxicity ofmuconaldehyde, a hemato-
toxin (9), has yet to be elucidated.
BQ and HQ have been shown, by the application of
HPLC and physical methods (7), to form adducts invitro
with calfthymus DNA, deoxyguanosine (dG), and deoxy-
adenosine (dA). The majoradduct formedby the reaction
of dG with BQ has been characterized as (3'OH) ben-
zetheno(Nl,N2)deoxyquanosine (7). In addition to BQ and
HQ, phenol, catechol, BT, and 14C-benzene, have been
shown toformadducts invitro with DNAinthe liverand
in bone marrow mitoplasts prelabeled with 3H-dGTP or
3H-dATP, as determined by the profiling of DNA
hydrolysate on a Sephadex LH-20 column (8). Sevengua-
nine and two adenine adducts have been detected with
benzene inthis system (8). The question as to whetherad-
ducts similar to the in vitro products are generated in
vivo has notbeen addressed, although administration of
4C- or 3H-benzene to rats and mice has been shown to
cause incorporation oflow-level radioactivity into DNA
ofliver, kidney, spleen, and bone marrow(10,11). In the
present studies, we have addressed this question using
a highly sensitive nuclease Pi-enhanced 32P-postlabeling
assay(12,13), which allows the detection ofaromatic andREDDYETAL.
bulky nonaromatic adducts at a frequency as low as 1
modification per 109- 10 DNA nucleotides. Our results
show that in vitro adductsgenerated with the above aro-
matic benzene metabolites are not formed in vivo at de-
tectable levels in DNA samples isolated from the liver,
kidney, and mammary gland ofratsgivenbenzene for 10
weeks. DNA from the Zymbal gland, however, showed
three adducts, which appear not to correspond to the in
vitro adducts from aromatic metabolites.
Materials and Methods
The sources of chemicals and biochemicals have been
given inthe accompanyingpaper(14), exceptwhere speci-
fied below.
Tovalidate the suitability ofthe 32P-postlabelingassay
for benzene-type adducts, BQ-modified DNA (BQ-DNA)
was prepared by incubation of rat kidney DNA (3 mM
DNA-P) with BQ (9 mM, Aldrich Chemical Co.) at 370C
for 12 hr, followed byprecipitation with ethanol. Control
was carried out without the addition ofBQ or DNA. To
reduce the extent ofadduction, BQ-DNA was mixedwith
unadducted DNA at the ratio of 1 to 300.
Female Sprague-Dawley rats, 4 months of age and
weighing about 280 g (Charles River Laboratories, Ra-
leigh, NC), were maintained on standard laboratory diet
and water ad libitum. To prepare invivo benzene-DNA
samples, groups ofrats (4pergroup) weregiven, by oral
gavage, 200 or 500 mg/kg benzene in olive oil (3 mL/kg)
every day, 5 days/weekfor 1 day, 1 week, 5weeks, or 10
weeks; the dose was switched from 500 to 200 mg/kg at
week4toreduce ratmortalityfrombenzene toxicity. The
rats were sacrificed at 24 hrafter dosing, and thefollow-
ingtissues were collected: liver, kidney, mammarygland,
bone marrow (femur), and Zymbal gland. DNA was iso-
latedfromthe tissuesby amodified digestion andextrac-
tion procedure as described previously (15), except that
the volumes ofreagents were reduced 3-fold in the case
of Zymbal glands. DNA modified in vivo with 2-acetyl-
aminofluorene(AAF), used as apositive control, waspre-
pared from the Zymbal glands of rats at 24 hr after a
daily oral dosingof40mg/kgAAF for5days(14). The de-
tection and quantitation ofadducts in DNA samples (15
pg each) were accomplished by a nuclease Pi-enhanced
P-postlabeling assay (12,13) coupled with TLC per-
formed according to method A in the accompanying pa-
per (14). 32P-Labeling of adducts without exposure of
DNA digests to nuclease P1, i.e., the standardprocedure,
was according to previous conditions (12,16).
Results
Validation of Nuclease PI Version of the
32P-Postlabeling Assay
Detection ofaromatic DNAadductsby32P-postlabeling
can be enhanced three orders of magnitude by the
pretreatment of DNA digests with nuclease P1, which
dephosphorylates normal nucleotides but not most aro-
matic adducted nucleotides (12,13). Since some adducted
nucleotides are, however, dephosphorylated with
nuclease P1, resultingintheirlowrecoveryorloss(12,13),
itwasnecessarytovalidate thenucleasePi-enhanced32p-
postlabeling assayforadducts derivedfromaromaticben-
zene metabolites.
The validation ofthe 32P-postlabeled adduct assay was
carried out employing in vitro adducts. One major and
several minor 32P-postlabeled adduct fractions were de-
tectedwith invitro BQ-DNA(Fig. 1B)butnotwith con-
trol DNA (Fig. 1A). These adducted nucleotides were
found to be virtuallyresistant to 3'-dephosphorylation by
nuclease P1, since the adductpatterns, aswell as adduct
recoveries (data not shown), were similarwith and with-
out exposure (i.e., standard procedure) (Fig. 1B and 1D)
to theenzyme. Thenuclease Pi-mediated assaywas, how-
ever, about three orders of magnitude more sensitive
than the standard procedure, as evident from the ob-
served enhancement of 32p incorporation into adducts
(data not shown)andthe approximately 500times shorter
film exposure required for adduct detection. Adduct 1
composedapproximately82% oftotal DNAmodifications,
which corresponded to 400 adducts per 107 nucleotides.
Reducing DNAmodification about300times by dilution
FIGURE 1. Comparison ofnuclease Pi and standard assays for BQ-DNA
adducts. Autoradiograms of 32P-maps of labeled digests prepared
from the indicated DNA samples with (A, B) and without(C, D) ex-
posure to nuclease Pi. DNA specimens (15Mg) were digested and la-
beledunder standardandnucleasePi conditions(12). Labeled adducts
were purified, transferred in situ(23), and resolvedby PEI-cellulose
TLC according to method A(14), except that the development in D3
solvent (bottom to top) was to 12.5 cm. Autoradiography was per-
formed at230C for30min(A,B)and at -800C for2days(C,D). Weak
spots have been circled. OR, origin. The sensitivity ofX-ray film is
4 to 5 times higher at -800C than at 230C.
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with unadducted kidney DNA still permitted the detec-
tion ofBQ adducts, but an increase in background radi-
oactivity was noticed both in control andtreated samples
(Fig. 2). The background spots, some ofwhich correspond
to endogenous adducts (I-compounds) (17), reduced the
sensitivity ofdetection foradducts ofinterest. The limit
ofdetection ofBQ-specific adducts variedfrom 1 to 10ad-
ducts per 10'0 DNA nucleotides, depending on the posi-
tion ofan adduct inrelation to endogenous adducts. For
example, adduct 3 couldbe detected at ahigher sensitiv-
ity than adduct 1 (Fig. 2), which in turn was detected at
a greater sensitivity than adduct 2.
Usingthe 32P-postlabeling assay, we detected a major
product chromatographically identical to adduct 1 (Fig.
1A and 1B) when deoxyguanosine 3'-monophosphate was
reacted with BQ (data not shown), showing that adduct
1 is aguanine derivative. The reaction ofBQwith dG has
been shown to generate (3'OH)benzetheno(Nl,N2)dG as
the major derivative by HPLC and NMR analyses (7).
These results, aswell asthefindingthat DNA adducts
are readily detectable in a dose-related fashion in Zym-
bal glands treated in culture with phenol, HQ, BQ,
catechol, and BT (14), indicated that the nuclease PI ver-
sion of32P-postlabeling assay is applicable for the sensi-
tive measurement ofadducts derivedfromthesebenzene
metabolites.
Analysis of In Vivo Adducts
The validated nuclease Pi-mediated 32P-postlabeling
procedure was applied to the detection of adducts in
DNAsamples isolated fromtissues at24 hrafter a daily
oral gavage dose of200 to 500 mg/kg benzene for 1 day,
1 week, 5weeks, or 10weeks. Noaromatic adducts were
detected unequivocally in the liver, kidney, and mam-
marygland at any ofthe time points, while the Zymbal
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FIGURE 2. Effect of lowering of DNA modifications on the 32P-post-
labeling assay's sensitivity. In vitro BQ-DNA was diluted 300-fold
with unadducted kidney DNA and was analyzed by the nuclease PI
method. See the legend of Fig. 1 for additional details. Note that
chromatographic development in the vertical direction was longer
(20 cm) than that performed for maps shown in Fig. 1. Autoradiog-
raphy was at -800C for 15 hr. A, B, and C indicate reference back-
ground spots.
glands showed adducts only after 10weeks oftreatment.
These findings are illustrated in Figure 3 with 32P-maps
derived from 5-week and 10-week DNA samples. For
liver, kidney, and mammary glands, 32p fingerprints of
5-weektreated DNA specimens were both qualitatively
andquantitativelyvery similarto those obtainedwiththe
corresponding control samples, indicating that benzene
failed to elicit aromatic adducts at detectable levels of 1
adduct in 109 nucleotides. Certain extra spots markedby
arrows were seen inconsistently in treated samples and
were not detectable after 10 weeks of treatment (maps
not shown). The 32P-map of Zymbal gland DNA after 5
weeks was also similar to that ofcontrol DNA, while the
10-week sample showed three extra spots indicative of
adducts. Adductlevels correspondedto 4lesionsper 109
DNA nucleotides. Some spots indicated by arrows,
presumably endogenous adducts, were reduced after 10
weeks ofbenzene treatment. Bone marrow DNA isolated
from rats treated with benzene for 1 day and 1 week
failed to show adducts (maps not shown). Adducts were
readily detectable with in vitro BQ-DNA and in vivo
AAF-DNA from Zymbal glands, bothbeing used in this
study as positive controls.
Discussion
Nuclease Pi-enhanced 32P-postlabeling analysis re-
vealed no DNA adducts in the liver, kidney, bone mar-
row, and mammary gland of rats given an oral gavage
dose ofbenzene for 1 day, 1 week, 5 weeks or 10 weeks.
Since the 32P-postlabeling assay is suitable for detection
of DNA adducts derived in vitro from phenol, HQ, BQ,
catechol, and BT(Fig. 1)(14), it canbe concluded thatad-
ducts from these aromaticmetabolites are notformed in
vivo following benzene administration or are formed be-
low detectable levels of 1 adduct in 109 DNAnucleotides,
i.e., 0.003 fmole/4g DNA. It is conceivable that the aro-
matic metabolites formed from the metabolism of ben-
zene in vivo (4,5) either undergo conjugation or bind to
proteins in tissues-both are processes that can inhibit
DNA adduct formation.
The postlabeling assay results are not in agreement
withthe direct labelingfindings that show a lowlevel of
radioactivity incorporated into the tissue DNA samples
following 3H- or 4C-benzene administration to rats
(10,11). This discrepancy can, however, beexplainedifthe
in vivo adducts are predominantly nonaromatic and po-
lar, as are those probably derivedfromtheputative open-
ring derivative, muconaldehyde (6). In contrast to direct
labeling, the 32P-postlabeling assay, under the conditions
described, does not allow the recovery of such adducts.
The most likely steps in the procedure at which adduct
loss occurs are nuclease Pi treatment of DNA digests
(16), which can cause 3'-dephosphorylation of small ad-
ducts (16), and the purification of adducts by PEI-
cellulose TLC. However, no adductswere detected when
several variations ofpostlabeling techniques were tried
(data not shown). These included: a) labeling ofadducts
by standard (16,17) and intensification conditions (18),
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neither ofwhich involves the exposure of DNA digests
to nuclease P1; b) the resolution of adducts by a combi-
nation of reverse-phase TLC and PEI-cellulose TLC
(15,19,20), which allows the recovery of nonaromatic,
bulky adducts (14); and c) the separation of adducts by
two-dimensional PEI-cellulose TLC alone (16,21,22),
Benzene Liver
Control Mammary Gland
Control Zymbal Gland,
1Owk
which facilitates the recovery of simple alkylated prod-
ucts. These variations ofpostlabelingare, however, three
to five orders of magnitude less sensitive than the en-
hanced procedure using nuclease P1 (12-14). Therefore,
the enhancement ofthe 32P-postlabelingassay's sensitiv-
ity for small adducts by removal of unadducted nucleo-
........ Y-.-.............::"
Control Kidney
5 wk Benzene Zymbal Gland,
5 wk
Benzene ZymbW Gland, In Vitro BQ-DNA
10 wk (1:300 dilution)
FIGURE 3. Autoradiograms of 32P-maps obtained with DNA samples isolated from the indicated control and benzene-treated tissues. Auto-
radiography was performed at -800C for 48 hr (mammary glands) and 17 hr (others). A, B, and C indicate reference background spots. Adduct
1 seen with AAF-DNA has been identified previously as dpGp-C8-(N2-AF) and adduct 2 as dpGp-N2-(C3-AAF) (17).
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tides in DNA digests by HPLC prior to 32P-labeling
would probably assist in the detection of ring-opened
derivatives presumably formedwith 3H- or "4C-benzene
(10,11).
The detection of aromatic DNA adducts in Zymbal
glands after 10weeks ofbenzene treatment (Fig. 3)may
relate to tumor formation in this organ (2,3). These ad-
ducts apparently did not correspond chromatographically
to the major adduct ofBQ(Figs. 1 and2) orto the major
adductsgenerated bythe interaction ofphenol, HQ, BQ,
catechol, and BTwith DNAin Zymbalglands maintained
in culture (14). Adduct quantities from the in vivo Zym-
bal gland DNA are too low (".' 0.01 fmole) to perform
structural analysis by physicochemical methods, and
thus, it is not possible to identify the benzene metabo-
lite(s) present in the 32P-postlabeled adducts. More data
is needed to support the detection of in vivo adducts,
since thisresult isfrom a single time point, i.e., 10weeks
(Fig. 3). Experiments indicating either the accumulation
and persistence ofthe adducts upon benzene treatment
for a period longer than 10 weeks or the formation of
identical adducts in other target organs should provide
such supportive data.
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